At a glance
ClinicalIndex Comparison RecordN/ACompleted· 86 enrolled
Drug / intervention
denosumabdrug
Likely dose
denosumab 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index
In Brief
An observational study evaluating denosumab for Osteoporosis and Bone Fracture. Completed, enrolled 86 participants across 1 site.
Detailed Summary
The purpose of this study is to validate the long-term benefit of denosumab for osteoporosis treatment in a real-world clinical practice setting. We hypothesize that continued therapy (36+months) with denosumab will increase both trabecular bone score (TBS) and femur strength index (FSI) and reduce fracture and other bone health risks among post-menopausal women with osteoporosis.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis, Bone Fracture
CountriesUnited States
CollaboratorsAmgen
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartApr 2015
First PostedMay 2015
Primary CompletionJun 2016
TodayJul 2026
First PostedMay 6, 2015
Enrollment StartApr 1, 2015
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 11.2 years ago
Interventions
denosumabdrug
Patients will receive denosumab 60 mg subcutaneously every six months as part of their standard osteoporosis treatment.